Contents | Next article | Previous article
Journal 'Cytokines & inflammation', 2005, No. 2
|
Original Articles
|
Number 2'2005
|
POSSIBLE APPLICATION OF RONCOLEUKIN FOR LAK-THERAPY IN OVARIAN CANCER
E.Y. Zlatnik, L.Y. Golotina
Roncoleukin, a recombinant IL-2, was studied for the possibility of application by method of LAK-therapy. The lymph of ductus thoracicus of ovarian cancer patients receiving also autolymphochemotherapy was used as a source of lymphocytes. The immunobiologic activity of lymphocytes was studied after a 30-min incubation with Roncoleukin and also after cultivation during 24 and 48 hours. The increase of T cell proliferation, autocrine stimulation of IL-2 production, and increase of NK cell cytotoxicity were observed. A sensitizing effect of Roncoleukin on K562 target cells was shown as well: Roncoleukin increased the K562 cell sensitivity to NK-lysis. LAK-therapy with Roncoleukin-treated lymph cells was applied to ovarian cancer patients as a part of their complex treatment. The achieved effect allows considering the method to be perspective for therapy of ovarian cancer. (Cytokines and Inflammation. 2005. Vol. 4, № 2. P. 54-58.)
Keywords: Roncoleukin, ovarian cancer, lymph, LAK-therapy.
Contents | Next article | Previous article
|
|
![[About us] Journal 'Cytokines & Inflammation'](/images/Logo.gif){kind=logo}
